Modakafusp alfa
As of the edition of 20 October 2026, Modakafusp alfa is a protein: stopped in 2024; acts on CD38.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Protein
- Registered trials
- 5, 5 stopped early
- Disease areas
- Cancer; Blood and lymph; Heart and blood vessels; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Modakafusp alfa.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | P28907 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| Phase 2 | 3 | 0 | 0 | 3 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Teva | Lead sponsor of trials | 2017 to now |